The Goldman Sachs Group Has Lowered Expectations for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its target price lowered by The Goldman Sachs Group from $22.00 to $19.00 in a research report released on Thursday,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other brokerages have also commented on KVUE. JPMorgan Chase & Co. decreased their target price on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. UBS Group decreased their price objective on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, July 17th. Canaccord Genuity Group dropped their target price on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Finally, Barclays lowered their price objective on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $22.46.

Kenvue Price Performance

KVUE opened at $15.80 on Thursday. The company has a market capitalization of $30.31 billion, a P/E ratio of 21.34, a PEG ratio of 2.27 and a beta of 0.72. The company has a 50-day moving average of $19.71 and a 200-day moving average of $21.57. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue has a 1-year low of $15.47 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 5.3%. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently made changes to their positions in the business. Jacobs & Co. CA boosted its position in shares of Kenvue by 31.4% during the third quarter. Jacobs & Co. CA now owns 253,617 shares of the company’s stock worth $4,116,000 after buying an additional 60,585 shares during the period. Corient Private Wealth LLC increased its position in Kenvue by 1.2% in the 2nd quarter. Corient Private Wealth LLC now owns 413,221 shares of the company’s stock valued at $8,649,000 after acquiring an additional 4,785 shares during the period. Valeo Financial Advisors LLC raised its stake in Kenvue by 11.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 16,429 shares of the company’s stock valued at $344,000 after acquiring an additional 1,688 shares in the last quarter. V. M. Manning & CO. Inc. acquired a new position in Kenvue during the 2nd quarter worth $377,000. Finally, Q3 Asset Management bought a new position in shares of Kenvue in the second quarter worth $284,000. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.